SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Foxwoods Man, drkazmd65
Search This Board:
Last Post: 12/8/2016 11:18:03 PM - Followers: 173 - Board type: Free - Posts Today: 0

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
SureTrader
CVM News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 12/08/2016 10:46:09 AM
CVM News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 12/05/2016 06:04:57 AM
CVM News: Current Report Filing (8-k) 12/02/2016 05:23:43 PM
CVM News: CEL-SCI Announces Pricing of $4.25 Million Public Offering of Common Stock and Warrants 12/02/2016 07:00:00 AM
CVM News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 12/01/2016 04:14:33 PM
News News Alert: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 12/08/2016 10:46:09 AM
PostSubject
#8718  Sticky Note Do with this information what you will,... I drkazmd65 09/26/16 01:49:06 PM
#7838  Sticky Note $CVM recent news/filings mick 01/18/16 02:09:58 PM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#9641   oh... man... that is sneaky... lightrock 12/08/16 11:18:03 PM
#9640   Well, it was like a zen moment. lightrock 12/08/16 09:31:18 PM
#9639   Imo, this is basis of sec investigation, it learning curve 12/08/16 09:24:24 PM
#9638   Mesmerizing learning curve 12/08/16 09:21:49 PM
#9637   What was your epiphany? I always prefer to learning curve 12/08/16 09:21:00 PM
#9636   Cel-Sci Corp. ($0.0 (CVM) mick 12/08/16 09:03:56 PM
#9635   CVM News: Prospectus Filed Pursuant to Rule 424(b)(5) mick 12/08/16 09:03:33 PM
#9634   Would have really liked to see these statements trickledownfacists 12/08/16 08:34:41 PM
#9633   Read the full statement and make an informed remark.... trickledownfacists 12/08/16 08:02:42 PM
#9632   The heck! Now they are telling us ducruacuteo11 12/08/16 07:52:09 PM
#9631   On one share traded..... trickledownfacists 12/08/16 07:30:41 PM
#9630   12.5% pop after hours to $0.135 lightrock 12/08/16 06:50:34 PM
#9629   To make it more interesting, out of the lightrock 12/08/16 05:02:10 PM
#9628   Maybe we could.... Foxwoods Man 12/08/16 04:28:58 PM
#9627   Agreed. Sounds like it was not released for a drkazmd65 12/08/16 04:21:11 PM
#9626   I totally assumed it was the same as Foxwoods Man 12/08/16 03:37:04 PM
#9625   Agreed all - especially since there was no drkazmd65 12/08/16 03:26:39 PM
#9624   You would think that if there is risk Foxwoods Man 12/08/16 03:20:15 PM
#9623   Affirm trickledownfacists 12/08/16 03:16:41 PM
#9622   Remember the toxicity of Nivolumab and Ipilimumab. lightrock 12/08/16 03:14:01 PM
#9621   The rest of that paragraph... On one occasion, in trickledownfacists 12/08/16 02:49:49 PM
#9620   Our Phase 3 Study has been placed Foxwoods Man 12/08/16 02:46:31 PM
#9619   Well at least the new filing tells us trickledownfacists 12/08/16 02:37:07 PM
#9618   I guess I'm crazy, bought another 10000@ .12 Turney 12/08/16 12:01:50 PM
#9617   Now let's settle one of those things before trickledownfacists 12/08/16 11:08:03 AM
#9616   Today I feel older and wiser suddenly. lightrock 12/08/16 10:54:02 AM
#9615   Lordy I hope so! drkazmd65 12/08/16 10:51:17 AM
#9614   Up on big volume. Maybe we've put in Turney 12/08/16 10:40:33 AM
#9613   Hard to believe where we are at now steve2150 12/08/16 08:11:55 AM
#9612   Yep. This is my team set to kick a$$ lightrock 12/08/16 01:14:37 AM
#9611   I disagree almost entirely with everything you said. learning curve 12/08/16 01:13:53 AM
#9610   Amen. trickledownfacists 12/07/16 10:00:38 PM
#9609   I am in it for the eventual finish....one Foxwoods Man 12/07/16 09:48:15 PM
#9608   If you feel that way are you going Turney 12/07/16 09:41:41 PM
#9607   Should hear about the offering tomorrow, would like trickledownfacists 12/07/16 06:05:08 PM
#9606   For one, I am happy to see the lightrock 12/07/16 05:43:44 PM
#9605   I don't thing anyone knows anything yet on warfaretrader 12/07/16 04:51:43 PM
#9604   Very well said, the study must go on sinity 12/07/16 03:53:21 PM
#9603   The only thing I can see is they trickledownfacists 12/07/16 03:34:37 PM
#9602   It could be that they had to have Turney 12/07/16 03:32:56 PM
#9601   You are spot on and I said similar Foxwoods Man 12/07/16 03:19:54 PM
#9600   Either way, it ain't good! Here is ducruacuteo11 12/07/16 03:16:20 PM
#9599   Too many things happened at once. steve2150 12/07/16 10:46:29 AM
#9598   I agree... Foxwoods Man 12/07/16 09:37:32 AM
#9597   http://mobile.outsourcing-pharma.com/Clinical-Development/Almac-inVentiv-announc trickledownfacists 12/07/16 09:33:27 AM
#9596   Investors have no confidence in mgt steve2150 12/07/16 08:44:04 AM
#9595   I wouldn't even be able to provide a learning curve 12/07/16 04:22:29 AM
#9594   Didn't notice the block. learning curve 12/07/16 02:39:38 AM
#9593   Taking a look around the block, so to lightrock 12/07/16 02:11:45 AM
#9592   Maybe I don't get the exercise? learning curve 12/07/16 01:15:52 AM
PostSubject